Streetbeat News

BPTH

Bio-Path Holdings, Inc.

https://www.biopathholdings.com

Industry

Biotechnology

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Open

0.90

Mkt cap

3.3M

Volume

43K

High

0.92

P/E Ratio

-0.06

52-wk high

12.40

Low

0.87

Div yield

N/A

52-wk low

0.80

Bio-Path Holdings has received an Israeli patent (No. 269608) for compositions using P-ethoxy nucleic acids aimed at STAT3 inhibition, targeting cancer or autoimmune disease treatments.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 3:44 pm

Bio-Path Holdings (NYSE:BPTH) has seen a decrease in short interest, now at 8.96% of its float, down 4.27% from the last report. With 67 thousand shares sold short, it would take about 1.92 days to cover all short positions. This change in short interest could indicate a shift in market sentiment towards BPTH, potentially signaling a more bullish outlook. The company's short interest is higher than its peer group average of 5.10%, suggesting it is more heavily shorted than similar companies.

Portfolio Pulse from Benzinga Insights

May 01, 2024 | 6:00 pm

Vaxxinity, Inc. announced its intention to voluntarily delist and deregister its Class A common stock, causing a sharp decline in its shares by around 55%. Other stocks experienced significant movements, with Matterport, Inc. seeing a jump due to an acquisition announcement by CoStar Group, and various companies reporting gains due to positive developments such as USDA approvals, IPO pricing, and compliance regains. Conversely, several companies faced declines due to negative news such as wind-down activities, delisting determinations, and price reductions.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 5:26 pm

In Monday's intraday session, several healthcare stocks experienced significant movements. NKGen Biotech led the gainers with a 33.8% increase, while Vaxxinity saw the largest decline among the losers, dropping 52.9%. Other notable movers included MSP Recovery, Assure Holdings, ProKidney, iSpecimen, GlucoTrack, Hepion Pharmaceuticals, Bio-Path Holdings, Inhibikase Therapeutics, Telomir Pharmaceuticals, and Ocean Biomedical. Market capitalizations varied widely among these companies, reflecting diverse investor reactions to recent earnings reports and market dynamics.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 4:31 pm

Wang & Lee Group, Inc. (WLGS) shares surged 37.7% in pre-market trading after reporting improved FY23 financial results, with a reduced loss per share and increased revenue. Other stocks also showed significant movement in pre-market trading, with notable gainers including Redwoods Acquisition Corp. (RWOD), Zhongchao Inc. (ZCMD), and Trio Petroleum Corp. (TPET), among others. On the losing side, BioNexus Gene Lab Corp. (BGLC) and Tian Ruixiang Holdings Ltd (TIRX) saw significant drops, alongside other decliners.

Portfolio Pulse from Avi Kapoor

April 19, 2024 | 9:45 am

In Thursday's after-market session, several healthcare stocks experienced significant movements. Bio-Path Holdings, Biora Therapeutics, Mustang Bio, BIMI International Medical, Allarity Therapeutics, and China SXT Pharmaceuticals were among the gainers, with increases ranging from 6.06% to 9.0%. Conversely, Virpax Pharmaceuticals, iSpecimen, Portage Biotech, SINTX Technologies, Cyclo Therapeutics, and Benitec Biopharma saw declines between 6.16% and 18.2%.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 8:31 pm

Bio-Path Holdings, Inc. (BPTH) shares resumed trading after a temporary halt due to a circuit breaker trigger. The halt was likely due to significant volatility in the stock's price.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 6:10 pm

Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced a registered direct offering and concurrent private placement to institutional investors, selling 375,000 shares at $3.225 each, and issuing warrants for an additional 375,000 shares at $3.10 each. The transactions will increase the outstanding shares from 1,190,306 to 1,565,306, with H.C. Wainwright & Co., LLC as the placement agent. The offering is expected to close on April 19, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 6:01 pm

Roth MKM analyst Philip Shen has reiterated a Buy rating on Bio-Path Holdings (BPTH) and maintained a $40 price target. This reaffirms the firm's positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 5:57 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Bio-Path Holdings, Aileron Therapeutics, 23andMe Holding, SINTX Techs, iSpecimen, and Benitec Biopharma were among the gainers, with increases ranging from 25.62% to 67.1%. On the downside, SeaStar Medical Holding, Aptorum Group, NRX Pharmaceuticals, Genetic Technologies, Ontrak, and INVO Bioscience saw declines between 20.34% and 27.0%. These movements were influenced by recent earnings reports and market dynamics.

Portfolio Pulse from Benzinga Insights

April 18, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.